Literature DB >> 21717080

A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice.

Ming S Lin1, Hubert M Tse, Meghan M Delmastro, Suzanne Bertera, Caterina T Wong, Robert Lakomy, Jing He, Martha M Sklavos, Gina M Coudriet, Massimo Pietropaolo, Massimo M Trucco, Jon D Piganelli.   

Abstract

Previous studies by our group, using an experimental autoimmune thyroiditis (EAT) model in Strain 13 inbred guinea pigs, resulted in T cell-mediated delayed hypersensitivity; however, autoantibodies proved not to be cytotoxic to thyroid epithelial cells in the presence or absence of complement proteins. Albeit, T cell-mediated lymphocyte cytotoxicity began to diminish sharply concomitantly with increasing titers of circulating autoantibodies, indicating a skewing of the self-reactive response and amelioration of the EAT. Furthermore, immunization of guinea pigs with thyroglobulin in incomplete Freund's adjuvant (IFA) generated a high titer of antithyroglobulin antibodies and proved to inhibit thyroiditis. These observations indicated that the shift in the immune response from Th1 to Th2 and the production of antibodies were likely responsible for ameliorating EAT. Based upon these results, we extrapolated our studies to design a multivalent vaccine, which shows promise in preventing/reversing T1D in NOD mice. A small pilot study was conducted in which a total of 34 mice, 20 non-immunized controls and 14 immunized with syngeneic islet lysate, were monitored for mean day to diabetes for a total of 28 weeks. Immunization of NOD animals with syngeneic islet lysates resulted in a significant delay in diabetes onset (P < 0.001) as compared to non-immunized controls. To further assess the vaccine's efficacy, robustness, and delay of disease, a large-scale experiment was conducted and monitored for 32 weeks using 106 mice, 64 non-immunized controls and 42 immunized with syngeneic islet lysate. At the end of the study, 90% of the non-immunized group developed diabetes, while less than 25% of the immunized group became diabetic (P < 0.0001). The protective effect, as a result of vaccination, correlated with an increase in the levels of IL-10 and IL-4 cytokines as well as a skewing to Th2-dependent isotype antibodies in serum. Strikingly, adoptive transfer of spleen cells from immunized animals into NOD.scid recipients provided protection against transfer of diabetes by diabetogenic spleen cells. The results of this study provide evidence that vaccination with islet lysate leads to a Th2-dependent skewing of the immune response to islet beta cells as a possible mechanism of protection. This strategy may be implemented as a possible vaccination protocol for arresting and/or preventing T1D in patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717080      PMCID: PMC4303903          DOI: 10.1007/s12026-011-8215-0

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  40 in total

1.  In vitro and in vivo studies on the mechanism of experimental autoimmune thyroiditis in guinea pigs.

Authors:  M S Lin; S B Salvin
Journal:  Cell Immunol       Date:  1976-12       Impact factor: 4.868

Review 2.  Autoreactive T-cell clones from the nonobese diabetic mouse.

Authors:  B Bergman; K Haskins
Journal:  Proc Soc Exp Biol Med       Date:  1997-01

Review 3.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Authors:  M A Atkinson; G S Eisenbarth
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

4.  Further studies on the mechanism of experimental autoimmune thyroiditis in guinea pigs. Properties of thyroid cytotoxic factor (TCF) and its relationship to pathogenesis of the disease.

Authors:  M S Lin; S B Salvin
Journal:  Cell Immunol       Date:  1976-12       Impact factor: 4.868

5.  Characterization of pancreatic T lymphocytes associated with beta cell destruction in the non-obese diabetic (NOD) mouse.

Authors:  T W Kay; I L Campbell; L C Harrison
Journal:  J Autoimmun       Date:  1991-04       Impact factor: 7.094

6.  Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice.

Authors:  Siri Atma W Greeley; Makoto Katsumata; Liping Yu; George S Eisenbarth; Daniel J Moore; Heidi Goodarzi; Clyde F Barker; Ali Naji; Hooman Noorchashm
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

7.  Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse.

Authors:  S Forsgren; A Andersson; V Hillörn; A Söderström; D Holmberg
Journal:  Scand J Immunol       Date:  1991-10       Impact factor: 3.487

8.  Imbalance in Th cell polarization and its relevance in type 1 diabetes mellitus.

Authors:  Charles Sia
Journal:  Rev Diabet Stud       Date:  2006-02-10

9.  Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner.

Authors:  Shabbir Hussain; Terry L Delovitch
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

Review 10.  Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits.

Authors:  W L Suarez-Pinzon; A Rabinovitch
Journal:  Int J Exp Diabetes Res       Date:  2001
View more
  12 in total

1.  Growth hormone prevents the development of autoimmune diabetes.

Authors:  Ricardo Villares; Dimitri Kakabadse; Yasmina Juarranz; Rosa P Gomariz; Carlos Martínez-A; Mario Mellado
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

2.  Mn porphyrin regulation of aerobic glycolysis: implications on the activation of diabetogenic immune cells.

Authors:  Meghan M Delmastro-Greenwood; Tatyana Votyakova; Eric Goetzman; Meghan L Marre; Dana M Previte; Artak Tovmasyan; Ines Batinic-Haberle; Massimo M Trucco; Jon D Piganelli
Journal:  Antioxid Redox Signal       Date:  2013-07-05       Impact factor: 8.401

3.  Soluble antigen arrays disarm antigen-specific B cells to promote lasting immune tolerance in experimental autoimmune encephalomyelitis.

Authors:  Brittany L Hartwell; Chad J Pickens; Martin Leon; Laura Northrup; Matthew A Christopher; J Daniel Griffin; Francisco Martinez-Becerra; Cory Berkland
Journal:  J Autoimmun       Date:  2018-07-13       Impact factor: 7.094

4.  Co-delivery of autoantigen and dexamethasone in incomplete Freund's adjuvant ameliorates experimental autoimmune encephalomyelitis.

Authors:  Laura Northrup; J Daniel Griffin; Matthew A Christopher; Lorena R Antunez; Brittany L Hartwell; Chad J Pickens; Cory Berkland
Journal:  J Control Release       Date:  2017-09-28       Impact factor: 9.776

5.  TLR2- and Dectin 1-associated innate immune response modulates T-cell response to pancreatic β-cell antigen and prevents type 1 diabetes.

Authors:  Subha Karumuthil-Melethil; M Hanief Sofi; Radhika Gudi; Benjamin M Johnson; Nicolas Perez; Chenthamarakshan Vasu
Journal:  Diabetes       Date:  2014-11-05       Impact factor: 9.461

6.  Immunisation With Immunodominant Linear B Cell Epitopes Vaccine of Manganese Transport Protein C Confers Protection against Staphylococcus aureus Infection.

Authors:  Hui-Jie Yang; Jin-Yong Zhang; Chao Wei; Liu-Yang Yang; Qian-Fei Zuo; Yuan Zhuang; You-Jun Feng; Swaminath Srinivas; Hao Zeng; Quan-Ming Zou
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

7.  Oral Administration of Silkworm-Produced GAD65 and Insulin Bi-Autoantigens against Type 1 Diabetes.

Authors:  Baoping Liu; Yuan Yue; Yun Yang; Yongfeng Jin
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

8.  Combining anti-IL-7Rα antibodies with autoantigen-specific immunotherapy enhances non-specific cytokine production but fails to prevent Type 1 Diabetes.

Authors:  Cristina Vazquez-Mateo; Justin Collins; Sarah J Goldberg; Maxx Lawson; Jaileene Hernandez-Escalante; Hans Dooms
Journal:  PLoS One       Date:  2019-03-25       Impact factor: 3.240

9.  Inhibition of Autoimmune Diabetes in NOD Mice by miRNA Therapy.

Authors:  Duncheng Wang; Iryna Shanina; Wendy M Toyofuku; Marc S Horwitz; Mark D Scott
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

Review 10.  Advances in the cellular immunological pathogenesis of type 1 diabetes.

Authors:  Min Li; Lu-Jun Song; Xin-Yu Qin
Journal:  J Cell Mol Med       Date:  2014-03-14       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.